健康人体内普卢利沙星对多索茶碱药动学的影响

目的:考察健康人体内达稳态时普卢利沙星对多索茶碱药动学的影响。方法:采用高效液相色谱法测定男性健康受试者给药前、后不同时间点多索茶碱的血药浓度。药-时数据用非线性程序WINNONLIN拟合,求得药动学参数。结果:多索茶碱在健康人体内呈一级吸收一室开放模型;合用前、后测得多索茶碱的主要药动学参数分别为:cmax(10.280±3.234)、(10.958±3.934)mg/L,t1/2a(0.218±0.179)、(0.298±0.182)h,tmax(0.883±0.458)、(1.222±0.475)h,t1/2β(4.770±3.311)、(5.537±3.577)h,AUC0-12hss(90.934±88.380)、(121.774±108.162)mg·h/L。结论:在该给药剂量下,两药合用在药动学上无明显的相互作用,提示两药临床上可以合用,但应注意监测多索茶碱的血药浓度。

Effects of Prulifloxacin on Pharmacokinetics of DoxofyUine in Healthy Volunteers

OBJECTIVE： To study the effect of prulifloxacin on pharmacokinetics of doxofylline in healthy volunteers. METHODS： The blood concentration of doxofylline in male healthy volunteers were measured by HPLC at different time points before and after medication. The plasma concentration-time data were accessed by non-linear program （WINNONL IN） and the pharmaco- kinetic parameters were obtained. RESULTS： The blood concentration-time curve of doxofylline was adequately fitted as one order adsorption one-compartment open model. Main pharmacokinetic parameters of doxofylline alone vs. combined with prulifloxacin were as follows： Cm （10.280 ± 3.234）mg/L vs.（10.958 ± 3.934）mg/L;t2a（0.218 ± 0.179）h vs. （0.298 ± 0.182）h;tm（0.883 ± 0.458） h vs.（1.222 ± 0.475）h;l,jz（4.770 ± 3.311）h vs.（5.537 ± 3.577）h;AUC-12h（90.934 ± 88.380）mg.h/L vs. （121.774 ± 108.162）mg.h/L. CONCLUSIONS： There is no obvious interaction of pharmacokinetics when doxofylline and prulifloxacin are co-administered. They can be taken simultaneously, but the blood concentration of doxofylline should be monitored.